Biomea Fusion BMF-650 (GLP-131) Phase I Topline Results Conference Call - BIOMEA FUSION INC

Explicit Guidance:

• Phase 2 Initiation: Plans to initiate two Phase 2 studies in Type 1 diabetes within the "next two quarters."
• T1D Readouts: Expect first 6-month response data from 36 Type 1 patients within the "next 18 months."
• Next Year Readouts (First Half): Anticipate two Phase 2 readouts: the 26-week primary endpoint for ICOVA-MENI in insulin-deficient patients and the primary endpoint for patients with inadequate glycemic control on GLP-1 therapy.
• End of Next Year: Expect results from combination studies of ICOVA-MENI with semaglutides (evaluating additional weight loss and muscle/bone preservation).
• Development Timeline: Target completion of 13-week subchronic toxicology studies (rats and cynomolgus monkeys) and initiation of a Phase 2 weight loss program within the "next 18 months" to secure End-of-Phase 2 meetings with the FDA.
• Capex/Financial Strategy: Explicitly state no intention to independently fund a large global obesity clinical program; capital will be deployed to advance ICVA-MENI and build BMF650 value for a strategic partnership/licensing arrangement.

Business-Segment Outlook:

• BMF650 (GLP-1 Receptor Agonist):
  • Pipeline: Advancing from Phase 1 to Phase 2; planning a "Cohort 6" (potentially with a partner) in an open, non-confined setting with 10–20 patients to validate weight loss signals and dosing.
  • Dosing Strategy: Evaluating a single-step titration (200mg to 400mg) or direct initiation at 400mg once daily to simplify administration; rejecting higher doses (e.g., 600mg) as excessive for long-term tolerability goals.
  • Target Exposure: Aiming to maintain exposure levels observed at the 400mg dose (~79,000 ng·h/mL) for long-term maintenance.
  • Differentiation: Focus on "persistence" (staying on treatment) and GI tolerability rather than maximizing short-term weight loss magnitude.
• ICOVA-MENI (MIP1411):
  • Focus Area: Remains the core value driver; advancing through Phase 2 in Type 1 and Type 2 diabetes to validate clinical signals and prepare for late-stage development.
  • Combination Studies: Investigating ICOVA-MENI combined with semaglutide for potential additive weight loss and organ protection.

Market and Competitive Outlook:

• Industry Problem: Highlights a critical market failure in current oral GLP-1s where 65% of users discontinue within the first year due to GI tolerability issues.
• Differentiation Gap: Believes the market needs a drug with a simpler dosing paradigm (one or zero titration steps) and superior tolerability to enable chronic use.
• Target Patient Value: Suggests a minimum of 10% weight loss is required for a drug to be worthwhile; views BMF650's profile (slower, sustained loss) as a solution to the "persistence" problem.
• Partnering Landscape: Open to partnerships with companies holding failed programs, programs lacking tolerability benefits, or new entrants to the space.

Macro / Industry Outlook:

• Market Structure: Anticipates that long-term winners in the obesity market will be those who can retain patients on therapy rather than just those with the highest peak efficacy.
• Regulatory Path: Plans to utilize the 13-week tox data to engage FDA for End-of-Phase 2 meetings to define the regulatory path for both Type 1 and Type 2 diabetes indications.

Strategic Initiatives:

• Cooperation/Partnership: Actively engaging in conversations with potential strategic partners for BMF650 licensing/late-stage development; no external funding expected from current cash for the global obesity program.
• Clinical Trial Design:
  • Cohort 6: Proposed Phase 1 expansion in a non-confined setting to clarify efficacy signals and test single-dose initiation.
  • Toxicology: Execution of 13-week subchronic toxicity studies in rats and cynomolgus monkeys.
• M&A/Business Development: Positioned to license BMF650 while retaining control of ICOVA-MENI; prioritizing capital discipline to avoid dilution while maximizing strategic value.

Risks and Headwinds to Outlook:

• Compliance Issues: Previous cohort (Cohort 4) showed anomalies potentially due to patient non-compliance, necessitating the confinement of Cohort 5 and the proposed open-label Cohort 6.
• Confinement Artifacts: Confined Cohort 5 data may be influenced by restricted food intake (placebo group consumed only 33% of food), requiring validation in an unrestricted setting.
• Uncertainty of "Real-World" Efficacy: Current Phase 1 weight loss data (6.1% over 4 weeks in confinement) must be validated in an outpatient setting where eating behavior is unmonitored.
• Heart Rate: Mild increase in heart rate (+6.4 bpm) observed, classified as a class effect expected to normalize over longer durations, but requires monitoring.
• Toxicology Delays: Failure to complete 13-week subchronic tox studies within expected timelines could delay Phase 2 initiation.

Management Tone on the Future:

• Confidence: High confidence in the "blowtorch vs. radiator" design hypothesis, citing the ability to separate efficacy from GI side effects.
• Validation: Describes results as "encouraging" and "sustained," emphasizing that the safety profile held even with rapid titration.
• Caution: Repeatedly cautions against over-interpreting small, confined cohort data; explicitly states Cohort 5 is "exploratory" and requires a larger, open study to confirm.
• Strategic Clarity: Firm in the decision not to pursue independent global obesity development, framing the company as a "value-building" platform for a partner rather than a full-scale commercializer of this specific asset.

Miscellaneous:

• Dose Specifics: 400 mg once daily identified as the target maintenance dose; 200 mg used as the starting dose for the single-step titration.
• Non-Clinical Correlation: Human exposure at 400mg (~79,000 ng·h/mL) aligns closely with efficacious exposure in NHP models (12–15% weight loss).
• Safety Profile: No severe adverse events, no dose modifications, and no discontinuations due to treatment-emergent adverse events in the 40 active participants of the MAD cohorts.